Citations (62)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Eduard Schmulenson, Nigina Zimmermann, Gerd Mikus, Markus Joerger & Ulrich Jaehde. (2021) Current status and future outlooks on therapeutic drug monitoring of fluorouracil. Expert Opinion on Drug Metabolism & Toxicology 17:12, pages 1407-1422.
Read now
Read now
Massimo Baraldo. (2008) The influence of circadian rhythms on the kinetics of drugs in humans. Expert Opinion on Drug Metabolism & Toxicology 4:2, pages 175-192.
Read now
Read now
Dorra Dridi, Mossadok Ben‐Attia, Mamane Sani, Nassim Djebli, François Ludovic Sauvage & Naceur A. Boughattas. (2008) Circadian Time‐Effect of Orally Administered Loratadine on Plasma Pharmacokinetics in Mice. Chronobiology International 25:4, pages 533-547.
Read now
Read now
Shuji Hishikawa, Koh-ichi Sugimoto, Eiji Kobayashi, Yuji Kumagai & Akio Fujimura. (2003) Dosing-Time-Dependent Variation in Biliary Excretion of Flomoxef in Rats. Chronobiology International 20:3, pages 463-471.
Read now
Read now
Francis Lévi. (2002) From circadian rhythms to cancer chronotherapeutics. Chronobiology International 19:1, pages 1-19.
Read now
Read now
Articles from other publishers (57)
Shudong Wang, Tiyao Liu, Chuanru Ren, Wenhao Wu, Zhiyuan Zhao, Shanchen Pang & Yuanyuan Zhang. (2023) Predicting potential small molecule–miRNA associations utilizing truncated schatten p-norm. Briefings in Bioinformatics 24:4.
Crossref
Crossref
Loredana Salerno, Valeria Sorrenti, Valeria Pittalà, Valeria Consoli, Maria N. Modica, Giuseppe Romeo, Agostino Marrazzo, Michela Giuliano, Paweł Zajdel, Luca Vanella & Sebastiano Intagliata. (2023) Discovery of SI 1/20 and SI 1/22 as Mutual Prodrugs of 5‐Fluorouracil and Imidazole‐Based Heme Oxygenase 1 Inhibitor with Improved Cytotoxicity in DU145 Prostate Cancer Cells. ChemMedChem 18:8.
Crossref
Crossref
Pattanaik Smita, Patil Amol Narayan, Kumaravel J & Prakash Gaurav. (2022) Therapeutic drug monitoring for cytotoxic anticancer drugs: Principles and evidence-based practices. Frontiers in Oncology 12.
Crossref
Crossref
Nicolas Laures, Céline Konecki, Mathias Brugel, Anne-Lise Giffard, Naceur Abdelli, Damien Botsen, Claire Carlier, Claire Gozalo, Catherine Feliu, Florian Slimano, Zoubir Djerada & Olivier Bouché. (2022) Impact of Guidelines Regarding Dihydropyrimidine Dehydrogenase (DPD) Deficiency Screening Using Uracil-Based Phenotyping on the Reduction of Severe Side Effect of 5-Fluorouracil-Based Chemotherapy: A Propension Score Analysis. Pharmaceutics 14:10, pages 2119.
Crossref
Crossref
Shumin Li, Zhongkai Xu, Majed Alrobaian, Obaid Afzal, Imran Kazmi, Waleed H. Almalki, Abdulmalik Saleh Alfawaz Altamimi, Fahad A. Al‐Abbasi, Khalid S Alharbi, Waleed M Altowayan, Tanuja Singh, Md Habban Akhter, Manish Gupta, Mahfoozur Rahman & Sarwar Beg. (2021) EGF‐functionalized lipid–polymer hybrid nanoparticles of 5‐fluorouracil and sulforaphane with enhanced bioavailability and anticancer activity against colon carcinoma. Biotechnology and Applied Biochemistry 69:5, pages 2205-2221.
Crossref
Crossref
Matthew Ng, Sylvia Chen, Whee Sze Ong, Akhila Balachander, Amanda Seet, Joe Yeong, Natalia Sutiman, Tony Kiat Hon Lim, Bernett Lee, Yu Amanda Guo, Wai Fook Leong, Sze Sing Lee, Justina Lam, Su Pin Choo, Anders Jacobsen Skanderup, Subhra Kumar Biswas, David Tai & Balram Chowbay. (2022)
A phase 1b study of
OXIRI
in pancreatic adenocarcinoma patients and its immunomodulatory effects
. International Journal of Cancer 151:3, pages 435-449.
Crossref
Crossref
Ya Niu, Xinyi Fan, Yaping Wang, Jiaxin Lin, Luchun Hua, Xiaobo Li, Ruizhe Qian & Chao Lu. (2022) Genome-wide CRISPR Screening Reveals Pyrimidine Metabolic Reprogramming in 5-FU Chronochemotherapy of Colorectal Cancer. Frontiers in Oncology 12.
Crossref
Crossref
Ehab S. EL Desoky. (2022) Therapeutic Dilemma in Personalized Medicine. Current Reviews in Clinical and Experimental Pharmacology 17:2, pages 94-102.
Crossref
Crossref
Lei Wang, Sarah Howlett & Sharadah Essapen. (2022) Treating patients with dihydropyrimidine dehydrogenase (DPD) deficiency with fluoropyrimidine chemotherapy since the onset of routine prospective testing—The experience of a large oncology center in the United Kingdom. Seminars in Oncology 49:2, pages 170-177.
Crossref
Crossref
Markella I Printezi, Aoife B Kilgallen, Marinde J G Bond, Urška Štibler, Marrit Putker, Arco J Teske, Maarten J Cramer, Cornelis J A Punt, Joost P G Sluijter, Alwin D R Huitema, Anne M May & Linda W van Laake. (2022) Toxicity and efficacy of chronomodulated chemotherapy: a systematic review. The Lancet Oncology 23:3, pages e129-e143.
Crossref
Crossref
Bharath S Padya, Aswathi R Hegde, Sadhana P Mutalik, Swati Biswas & Srinivas Mutalik. (2022) Analytical and bioanalytical HPLC method for simultaneous estimation of 5-fluorouracil and sonidegib. Bioanalysis 14:1, pages 29-45.
Crossref
Crossref
Rúben Araújo, Luís Ramalhete, Hélder Paz, Carina Ladeira & Cecília R.C. Calado. (2021) A new method to predict genotoxic effects based on serum molecular profile. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy 255, pages 119680.
Crossref
Crossref
Damla Ulker, Inci Barut, Erol Şener & Vural Bütün. (2021) Advanced liposome based PEGylated microgel as a novel release system for 5-fluorouracil against MCF-7 cancer cell. European Polymer Journal 146, pages 110270.
Crossref
Crossref
Devendra Choudhary, Hanmant Goykar, Kuldeep Rajpoot & Rakesh Kumar Tekade. 2021. Biopharmaceutics and Pharmacokinetics Considerations. Biopharmaceutics and Pharmacokinetics Considerations
163
194
.
Wael A. Mahdi, Afzal Hussain & Mohd. Ramzan. (2020) 5-Fluorouracil Loaded Biogenic and Albumin Capped Gold Nanoparticles Using Bacterial Enzyme—In Vitro-In Silico Gastroplus® Simulation and Prediction. Processes 8:12, pages 1579.
Crossref
Crossref
Bee Koon Gan, Kamal Rullah, Chean Yeah Yong, Kok Lian Ho, Abdul Rahman Omar, Noorjahan Banu Alitheen & Wen Siang Tan. (2020) Targeted delivery of 5-fluorouracil-1-acetic acid (5-FA) to cancer cells overexpressing epithelial growth factor receptor (EGFR) using virus-like nanoparticles. Scientific Reports 10:1.
Crossref
Crossref
Amitava Dasgupta & Matthew D. Krasowski. 2020. Therapeutic Drug Monitoring Data. Therapeutic Drug Monitoring Data
331
350
.
Theodore J. Wigle, Elena V. Tsvetkova, Stephen A. Welch & Richard B. Kim. (2019) DPYD and Fluorouracil-Based Chemotherapy: Mini Review and Case Report. Pharmaceutics 11:5, pages 199.
Crossref
Crossref
Jan H. Beumer, Edward Chu, Carmen Allegra, Yusuke Tanigawara, Gerard Milano, Robert Diasio, Tae Won Kim, Ron H. Mathijssen, Li Zhang, Dirk Arnold, Katsuki Muneoka, Narikazu Boku & Markus Joerger. (2018) Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5‐Fluorouracil Therapy. Clinical Pharmacology & Therapeutics 105:3, pages 598-613.
Crossref
Crossref
Yan Liu, Dongyang Zhao, Mengchi Sun, Wei Wei, Yingli Wang, Jiahua Zhou, Ruoshi Zhang, Jian Wang, Haotian Zhang, Zhonggui He, Qiming Kan & Jin Sun. (2018) Covalently mucoadhesive amphiphilic prodrug of 5-fluorouracil for enhanced permeation and improved oral absorption. Drug Delivery and Translational Research 8:3, pages 645-656.
Crossref
Crossref
Nattawut Leelakanok, Sean Geary & Aliasger Salem. (2018) Fabrication and Use of Poly(d,l-lactide-co-glycolide)-Based Formulations Designed for Modified Release of 5-Fluorouracil. Journal of Pharmaceutical Sciences 107:2, pages 513-528.
Crossref
Crossref
Shinji Kobuchi, Yukiko Yazaki, Yukako Ito & Toshiyuki Sakaeda. (2018) Circadian variations in the pharmacokinetics of capecitabine and its metabolites in rats. European Journal of Pharmaceutical Sciences 112, pages 152-158.
Crossref
Crossref
A. Le Naour & B. Couderc. 2017. Mesenchymal Stromal Cells as Tumor Stromal Modulators. Mesenchymal Stromal Cells as Tumor Stromal Modulators
295
333
.
Shinji Kobuchi, Asuka Hayashi, Mayu Taniguchi, Yukako Ito, Takao Tamura & Toshiyuki Sakaeda. (2016) Effects of a bolus injection of 5-fluorouracil on dihydropyrimidine dehydrogenase activity in rats receiving continuous infusion of 5-fluorouracil. Cancer Chemotherapy and Pharmacology 78:3, pages 517-523.
Crossref
Crossref
Sarah Leyking, Karin Budich, Kai van Bentum, Stephan Thijssen, Hashim Abdul-Khaliq, Danilo Fliser, Martina Sester & Urban Sester. (2015) Calcineurin inhibitors differentially alter the circadian rhythm of T-cell functionality in transplant recipients. Journal of Translational Medicine 13:1.
Crossref
Crossref
T. Katherine Tamai & David Whitmore. 2015. Circadian Medicine. Circadian Medicine
169
181
.
Arthur J. Weiss. (2015) A Hypothesis Concerning the Effect of Schedule on the Pattern of 5-Fluorouracil Toxicity. Journal of Cancer Therapy 06:03, pages 251-256.
Crossref
Crossref
Man Li, Zhen Liang, Xun Sun, Tao Gong & Zhirong Zhang. (2014) A Polymeric Prodrug of 5-Fluorouracil-1-Acetic Acid Using a Multi-Hydroxyl Polyethylene Glycol Derivative as the Drug Carrier. PLoS ONE 9:11, pages e112888.
Crossref
Crossref
Johanna Sistonen, Barbara Büchel, Tanja K Froehlich, Dominic Kummer, Stefano Fontana, Markus Joerger, André BP van Kuilenburg & Carlo R Largiadèr. (2014) Predicting 5-fluorouracil toxicity: DPD genotype and 5,6-dihydrouracil:uracil ratio. Pharmacogenomics 15:13, pages 1653-1666.
Crossref
Crossref
A. Ducournau, P. Lagarde, B. Henriques de Figueiredo, M. Antoine, C. Breton-Callu, A. Petit, B. Dallaudière & P. Sargos. (2014) Radiothérapie chez une patiente atteinte d’un cancer du sein et d’ostéogenèse imparfaite : à propos d’un cas. Cancer/Radiothérapie 18:2, pages 132-135.
Crossref
Crossref
Zhenze Liu, Jun Xi, Sven Schröder, Weigang Wang, Tianpei Xie, Zhugang Wang, Shisan Bao & Jian Fei. (2013)
Chimonanthus nitens
var.
salicifolius
Aqueous Extract Protects against 5-Fluorouracil Induced Gastrointestinal Mucositis in a Mouse Model
. Evidence-Based Complementary and Alternative Medicine 2013, pages 1-12.
Crossref
Crossref
Muhittin A. Serdar, Erdim Sertoğlu, Metin Uyanık, Serkan Tapan, Okhan Akın & Murat Cihan. (2010) Determination of 5-fluorouracil and dihydrofluorouracil levels by using a liquid chromatography–tandem mass spectrometry method for evaluation of dihydropyrimidine dehydrogenase enzyme activity. Cancer Chemotherapy and Pharmacology 68:2, pages 525-529.
Crossref
Crossref
Jinping Qiao, Chenxin Gu, Weihu Shang, Jinglei Du, Wei Yin, Meilin Zhu, Wei Wang, Mei Han & Weidong Lu. (2011) Effect of green tea on pharmacokinetics of 5-fluorouracil in rats and pharmacodynamics in human cell lines in vitro. Food and Chemical Toxicology 49:6, pages 1410-1415.
Crossref
Crossref
Inge R. H. M. Konings, Stefan Sleijfer, Ron H. J. Mathijssen, Peter de Bruijn, Inge M. Ghobadi Moghaddam-Helmantel, Linda M. van Dam, Erik A. C. Wiemer, Jaap Verweij & Walter J. Loos. (2010) Increasing tumoral 5-fluorouracil concentrations during a 5-day continuous infusion: a microdialysis study. Cancer Chemotherapy and Pharmacology 67:5, pages 1055-1062.
Crossref
Crossref
Chen Guang Yang, Joseph Ciccolini, Aurore Blesius, Laetitia Dahan, Danielle Bagarry-Liegey, Caroline Brunet, Arthur Varoquaux, Nicolas Frances, Hafedh Marouani, Antoine Giovanni, Rose-Marie Ferri-Dessens, Mohamed Chefrour, Roger Favre, Florence Duffaud, Jean-François Seitz, Michel Zanaret, Bruno Lacarelle & Cédric Mercier. (2010) DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity. Cancer Chemotherapy and Pharmacology 67:1, pages 49-56.
Crossref
Crossref
Nabil M. Abdel-Hamid & Mohamed A. Morsy. (2010) Novel Biochemical Pathways for 5-Fluorouracil in Managing Experimental Hepatocellular Carcinoma in Rats. Journal of Membrane Biology 234:1, pages 29-34.
Crossref
Crossref
M. Wasif Saif, Adrienne Choma, Salvatore J. Salamone & Edward Chu. (2009) Pharmacokinetically Guided Dose Adjustment of 5-Fluorouracil: A Rational Approach to Improving Therapeutic Outcomes. JNCI: Journal of the National Cancer Institute 101:22, pages 1543-1552.
Crossref
Crossref
Stefanie D. Krämer & Bernard Testa. (2009) The Biochemistry of Drug Metabolism – An Introduction. Chemistry & Biodiversity 6:10, pages 1477-1660.
Crossref
Crossref
Alfonso M Lostia, Luana Lionetto, Cristiano Ialongo, Giovanna Gentile, Antonella Viterbo, Paola Malaguti, Ida Paris, Luca Marchetti, Paolo Marchetti, Antonio De Blasi & Maurizio Simmaco. (2009) A Liquid Chromatography-Tandem Mass Spectrometry Method for the Determination of 5-Fluorouracil Degradation Rate by Intact Peripheral Blood Mononuclear Cells. Therapeutic Drug Monitoring 31:4, pages 482-488.
Crossref
Crossref
Rūta Švobaitė, Isabelle Solassol, Frederic Pinguet, Liudas Ivanauskas, Janine Brès & Françoise M M Bressolle. (2008) HPLC with UV or Mass Spectrometric Detection for Quantifying Endogenous Uracil and Dihydrouracil in Human Plasma. Clinical Chemistry 54:9, pages 1463-1472.
Crossref
Crossref
F. Lévi. (2008) Le système circadien : déterminant et cible de l’activité des traitements anticancéreux. Annales Pharmaceutiques Françaises 66:3, pages 175-184.
Crossref
Crossref
M-C Etienne-Grimaldi, J-M Cardot, E François, N Renée, J-Y Douillard, E Gamelin & G Milano. (2007) Chronopharmacokinetics of Oral Tegafur and Uracil in Colorectal Cancer Patients. Clinical Pharmacology & Therapeutics 83:3, pages 413-415.
Crossref
Crossref
Joseph Ciccolini, Cédric Mercier & Gérard Milano. 2009. Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response. Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response
249
265
.
Maud Beneton, Sophie Chapet, Hélène Blasco, Bruno Giraudeau, Michèle Boisdron-Celle, Régine Deporte-Fety, Fabrice Denis, Bérangère Narcisso, Gilles Calais & Chantal Le Guellec. (2007) Relationship between 5-fluorouracil exposure and outcome in patients receiving continuous venous infusion with or without concomitant radiotherapy. British Journal of Clinical Pharmacology 64:5, pages 613-621.
Crossref
Crossref
Francis Lévi, Christian Focan, Abdoulaye Karaboué, Virginie de la Valette, Danielle Focan-Henrard, Benoît Baron, Françoise Kreutz & Sylvie Giacchetti. (2007) Implications of circadian clocks for the rhythmic delivery of cancer therapeutics. Advanced Drug Delivery Reviews 59:9-10, pages 1015-1035.
Crossref
Crossref
Daniele Santini, Bruno Vincenzi, Gaia Schiavon, Marisa Di Seri, Vladimir Virzí, Bruno Spalletta, Marco Caricato, Roberto Coppola & Giuseppe Tonini. (2006) Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study. Cancer Chemotherapy and Pharmacology 59:5, pages 613-620.
Crossref
Crossref
S.A. Kaestner & G.J. Sewell. (2007) Chemotherapy Dosing Part I: Scientific Basis for Current Practice and Use of Body Surface Area. Clinical Oncology 19:1, pages 23-37.
Crossref
Crossref
Francesco Chiappelli, Olivia S. Cajulis, Audrey Navarro & David R. Moradi. 2007. Neuroimmunology of Sleep. Neuroimmunology of Sleep
27
58
.
Lori K. Mattison, Jeanne Fourie, Yukihiro Hirao, Toshihisa Koga, Renee A. Desmond, Jennifer R. King, Takefumi Shimizu & Robert B. Diasio. (2006) The Uracil Breath Test in the Assessment of Dihydropyrimidine Dehydrogenase Activity: Pharmacokinetic Relationship between Expired 13CO2 and Plasma [2-13C]Dihydrouracil. Clinical Cancer Research 12:2, pages 549-555.
Crossref
Crossref
Massimo Baraldo & Mario Furlanut. (2006) Chronopharmacokinetics of Ciclosporin and Tacrolimus. Clinical Pharmacokinetics 45:8, pages 775-788.
Crossref
Crossref
Ikuya Miki, Takao Tamura, Tsutomu Nakamura, Hiroo Makimoto, Noriko Hamana, Hitoshi Uchiyama, Daisuke Shirasaka, Yoshinori Morita, Hiroyuki Yamada, Nobuo Aoyama, Toshiyuki Sakaeda, Katsuhiko Okumura & Masato Kasuga. (2005) Circadian Variability of Pharmacokinetics of 5-Fluorouracil and CLOCK T3111C Genetic Polymorphism in Patients With Esophageal Carcinoma. Therapeutic Drug Monitoring 27:3, pages 369-374.
Crossref
Crossref
Hao Jiang, Jing Lu, Ji Jiang & Pei Hu. (2004) Important Role of the Dihydrouracil/Uracil Ratio in Marked Interpatient Variations of Fluoropyrimidine Pharmacokinetics and Pharmacodynamics. The Journal of Clinical Pharmacology 44:11, pages 1260-1272.
Crossref
Crossref
J. Ciccolini, C. Mercier, M.-F. Blachon, R. Favre, A. Durand & B. Lacarelle. (2004) A simple and rapid high-performance liquid chromatographic (HPLC) method for 5-fluorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activity. Journal of Clinical Pharmacy and Therapeutics 29:4, pages 307-315.
Crossref
Crossref
. (2004) Stability of 5-FU and Tegafur in Biological Fluids of Rats. Journal of Korean Pharmaceutical Sciences 34:3, pages 161-168.
Crossref
Crossref
R Mazzanti, A.L Giallombardo, E Mini, S Nobili, B Neri, U Arena, P Pantaleo, V Fabbroni, M Ghilardi, R Gattai & L Bandettini. (2004) Treatment of locally advanced hepatocellular carcinoma by hepatic intra-artery chemotherapy: a pilot study. Digestive and Liver Disease 36:4, pages 278-285.
Crossref
Crossref
Hao Jiang, Jing Lu & Jiang Ji. (2004) Circadian rhythm of dihydrouracil/uracil ratios in biological fluids: a potential biomarker for dihydropyrimidine dehydrogenase levels. British Journal of Pharmacology 141:4, pages 616-623.
Crossref
Crossref
Sabri Barutca, Ceyhun Ceyhan, Nezih Meydan, Banu Ozturk, Tarkan Tekten, Alper Onbasili, Gurhan Kadikoylu & Zahit Bolaman. (2004) A New Perspective on Cardiotoxicity of 5-Fluorouracil. Chemotherapy 50:3, pages 113-118.
Crossref
Crossref